Fulltext

Early Termination of a Prospective, Randomized Trial Comparing Teicoplanin and Flucloxacillin for Treating Severe Staphylococcal Infections

Calain, Philippe ; Krause, Karl-Heinz ; Vaudaux, Pierre ; Auckenthaler, Raymond ; Lew, Daniel ; Waldvogel, Francis ; Hirschel, Bernard

In: Journal of Infectious Diseases, 1987, vol. 155, no. 2, p. 187-191

Ajouter à la liste personnelle
    Titre
    • Early Termination of a Prospective, Randomized Trial Comparing Teicoplanin and Flucloxacillin for Treating Severe Staphylococcal Infections
    Auteur
    • Calain, Philippe. Division of Infectious Diseases, Hôpital Cantonal Universitaire, Genève, Switzerland
    • Krause, Karl-Heinz. Division of Infectious Diseases, Hôpital Cantonal Universitaire, Genève, Switzerland
    • Vaudaux, Pierre. Division of Infectious Diseases, Hôpital Cantonal Universitaire, Genève, Switzerland
    • Auckenthaler, Raymond. Division of Infectious Diseases, Hôpital Cantonal Universitaire, Genève, Switzerland
    • Lew, Daniel. Division of Infectious Diseases, Hôpital Cantonal Universitaire, Genève, Switzerland
    • Waldvogel, Francis. Division of Infectious Diseases, Hôpital Cantonal Universitaire, Genève, Switzerland
    • Hirschel, Bernard. Division of Infectious Diseases, Hôpital Cantonal Universitaire, Genève, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Infectious Diseases, 1987, vol. 155, no. 2, p. 187-191. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:296434
    Summary
    In a prospective, randomized trial, teicoplanin (at a 400-mg intravenous loading dose followed by 200 mg/day intravenously or intramuscularly) was compared with flucloxacillin (8 g/day) in patients with severe staphylococcal infections. Teicoplanin proved unsatisfactory for the following reasons: (1) failures or relapses were more frequent in the teicoplanin group, and (2) blood levels were difficult to predict and tended to be low 24 hr after the loading dose. Future trials with this agent should use much-higher doses